J. Goldman & CO LP Roivant Sciences Ltd. Transaction History
J. Goldman & CO LP
- $3.21 Billion
- Q3 2024
Shares
1 transactions
Others Institutions Holding ROIV
# of Institutions
311Shares Held
508MCall Options Held
1.26MPut Options Held
2.52M-
Sb Investment Advisers (Uk) LTD London, X065.9MShares$837 Million6.27% of portfolio
-
Qvt Financial LP New York, NY65.8MShares$836 Million73.2% of portfolio
-
Viking Global Investors LP54.1MShares$687 Million2.42% of portfolio
-
Vanguard Group Inc Valley Forge, PA41.7MShares$529 Million0.01% of portfolio
-
Black Rock Inc. New York, NY35.4MShares$449 Million0.01% of portfolio
About Roivant Sciences Ltd.
- Ticker ROIV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 704,382,976
- Market Cap $8.95B
- Description
- Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne...